[1]
|
Moon, K.W., et al. (2011) The correlation between durometer score and modified Rodnan skin score in systemic sclerosis. Rheumatology International, 32, 2465-2470.
|
[2]
|
Castro, S.V. and Jimenez, S.A. (2010) Biomarkers in systemic sclerosis. Biomarkers in Medicine, 4, 133-147.
doi:10.2217/bmm.09.79
|
[3]
|
Del Galdo, F., Shaw, M.A. and Jimenez, S.A. (2010) Proteomic analysis identification of a pattern of shared alterations in the secretome of dermal fibroblasts from systemic sclerosis and nephrogenic systemic fibrosis. American Journal of Pathology, 177, 1638-1646.
doi:10.2353/ajpath.2010.091095
|
[4]
|
Furst, D., et al. (2007) Systemic sclerosis—Continuing progress in developing clinical measures of response. Journal of Rheumatology, 34, 1194-200.
|
[5]
|
Matucci-Cerinic, M., et al. (2009) The complexity of managing systemic sclerosis: screening and diagnosis. Rheumatology (Oxford), 48, 8-13.
doi:10.1093/rheumatology/ken482
|
[6]
|
Grobner, T. and Prischl, F.C. (2007) Gadolinium and nephrogenic systemic fibrosis. Kidney International, 72, 260-264. doi:10.1038/sj.ki.5002338
|
[7]
|
Abignano, G., et al. (2011) Biomarkers in the management of scleroderma: An update. Current Rheumatology Reports, 13, 4-12. doi:10.1007/s11926-010-0140-z
|
[8]
|
Moinzadeh, P., et al. (2012) Biomarkers for skin involvement and fibrotic activity in scleroderma. Journal of the European Academy of Dermatology and Venereology, 26, 267-276. doi:10.1111/j.1468-3083.2011.04206.x
|
[9]
|
S, S. (2012) Stratified medicine approach for systemic sclerosis: State of the art and the need for clinical biomarkers. Unpublished Literature Review for Clinical Sciences Programme.
|
[10]
|
Clements, P.J., et al. (1993) Skin thickness score in systemic sclerosis: An assessment of interobserver variability in 3 independent studies. Journal of Rheumatology, 20, 1892-1896.
|
[11]
|
Kaldas, M., et al. (2009) Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis —Assessment of individual body sites in two large randomized controlled trials. Rheumatology (Oxford), 48, 1143-1146. doi:10.1093/rheumatology/kep202
|
[12]
|
Crawford, M., Woodman, R. and Ko Ferrigno, P. (2003) Peptide aptamers: Tools for biology and drug discovery. Briefings in Functional Genomics, 2, 72-79.
doi:10.1093/bfgp/2.1.72
|
[13]
|
Song, Q., et al. (2011) Peptide aptamer microarrays: Bridging the bio-detector interface. Faraday Discuss, 149, 79-92, 137-157. doi:10.1039/c005376g
|
[14]
|
Woodman, R., et al. (2005) Design and validation of a neutral protein scaffold for the presentation of peptide aptamers. Journal of Molecular Biology, 352, 1118-1133.
doi:10.1016/j.jmb.2005.08.001
|
[15]
|
Stadler, L.K., et al. (2011) Structure-function studies of an engineered scaffold protein derived from Stefin A. II: Development and applications of the SQT variant. Protein Engineering Design & Selection, 24, 751-763.
doi:10.1093/protein/gzr019
|
[16]
|
Murray, E., et al. (2007) Microarray-formatted clinical biomarker assay development using peptide aptamers to anterior gradient-2. Biochemistry, 46, 13742-13751.
doi:10.1021/bi7008739
|
[17]
|
Davis, J.J., et al. (2009) Peptide aptamers in label-free protein detection: 2. Chemical optimization and detection of distinct protein isoforms. Analytical Chemistry, 81, 3314-3320. doi:10.1021/ac802513n
|
[18]
|
(2012) Aptuscan unique affinity reagents.
http://www.avacta.com/affinity-reagents
|
[19]
|
Song, Q., McGonagle, D., et al. (2011) Scannin microbaray identifying protein biomarkers in inflammatory diseases. Leeds Institute of Molecular Medicine.
|
[20]
|
Nucleic acid purification.
http://www.bio-rad.com/webroot/web/pdf/lsr/literature/LIT-507G.pdf
|
[21]
|
Trusheim, M.R., Berndt, E.R. and Douglas, F.L. (2007) Stratified medicine: Strategic and economic implications of combining drugs and clinical biomarkers. Nature Reviews Drug Discovery, 6, 287-293. doi:10.1038/nrd2251
|
[22]
|
Hughes, B. (2009) Developing tools for stratified medicine. Nature Reviews Drug Discovery, 8, 919-920.
doi:10.1038/nrd3070
|
[23]
|
Ionescu, R., et al. (2010) Repeated teaching courses of the modified Rodnan skin score in systemic sclerosis. Clinical and Experimental Rheumatology, 28, S37-S41.
|
[24]
|
Furst, D.E., et al. (1998) The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. Journal of Rheumatology, 25, 84-88.
|
[25]
|
Postlethwaite, A.E., et al. (2008) A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. Oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease. Arthritis & Rheumatism, 58, 1810-1822.
doi:10.1002/art.23501
|
[26]
|
Khanna, D., et al. (2009) Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: A randomized, double-blind, placebo-controlled trial. Arthritis & Rheumatism, 60, 1102-1111.
doi:10.1002/art.24380
|
[27]
|
Rull, G. (2011) Systemic sclerosis (scleroderma).
http://www.patient.co.uk/doctor/Systemic-Sclerosis-(Scleroderma).htm
|
[28]
|
Ikuta, Y., et al. (2005) Highly sensitive detection of melanoma at an early stage based on the increased serum secreted protein acidic and rich in cysteine and glypican-3 levels. Clinical Cancer Research, 11, 8079-8088.
doi:10.1158/1078-0432.CCR-05-1074
|
[29]
|
Yamagishi, S., et al. (2006) Elevated serum levels of pigment epithelium-derived factor in the metabolic syndrome. Journal of Clinical Endocrinology & Metabolism, 91, 2447-2450. doi:10.1210/jc.2005-2654
|
[30]
|
Davis, J.J., et al. (2007) Peptide aptamers in label-free protein detection: 1. Characterization of the immobilized scaffold. Analytical Chemistry, 79, 1089-1096.
doi:10.1021/ac061863z
|
[31]
|
Laurenson, S., et al. (2011) Development of peptide aptamer microarrays for detection of HPV16 oncoproteins in cell extracts. Analytical Chemistry, 410, 161-170.
doi:10.1016/j.ab.2010.10.038
|